I. Forbes

发表

Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.

S. Bromidge, S. Dabbs, D. Davies, 1998, Journal of medicinal chemistry.

A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).

P J Lovell, J. Hagan, D. Middlemiss, 2000, Journal of medicinal chemistry.

SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist

A. Brown, D. Middlemiss, S. Bromidge, 1997, Neuropharmacology.

The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists.

Paul W Smith, I. Forbes, P. Wyman, 2010, Bioorganic & medicinal chemistry letters.

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.

I. Forbes, P. Groot, R. Ife, 2000, Bioorganic & Medicinal Chemistry Letters.

5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity.

I. Forbes, P. Ham, T. Blackburn, 1995, Journal of medicinal chemistry.

Synthesis, Biological Activity, and Molecular Modeling Studies of Selective 5‐HT2C/2B Receptor Antagonists.

Frank E. Blaney, S. Dabbs, D. Duckworth, 1997 .

Synthesis, biological activity, and molecular modeling of selective 5-HT(2C/2B) receptor antagonists.

S. Dabbs, D. Duckworth, I. Forbes, 1996, Journal of medicinal chemistry.

Identification of a novel series of selective 5-HT7 receptor antagonists.

I. Forbes, G. Riley, R. Ife, 2003, Bioorganic & medicinal chemistry letters.

SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.

I. Forbes, G. Riley, P. Jeffrey, 2002, Bioorganic & medicinal chemistry letters.

(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.

P J Lovell, J. Hagan, A. Brown, 1998, Journal of medicinal chemistry.

(R)‐3,N‐Dimethyl‐N‐ [1‐methyl‐3‐(4‐methylpiperidin‐1‐yl)propyl]benzenesulfonamide: The First Selective 5‐HT7 Receptor Antagonist.

I. Forbes, 1998 .

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.

D. Middlemiss, S. Lightowler, S. Bromidge, 2000, Journal of medicinal chemistry.

2' biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling.

C. Langmead, I. Forbes, R. Rivero, 2010, Bioorganic & medicinal chemistry letters.

2' biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR.

C. Langmead, J. Foley, I. Forbes, 2010, Bioorganic & medicinal chemistry letters.

N-Alkenyl nitrone dipolar cycloaddition routes to piperidines and indolizidines. Part 8. The scope of tandem reactions involving hydroxylamine-alkyne cyclisations☆

I. Forbes, A. Holmes, E. Davison, 1996 .

A tandem synthesis of (±)-euphococcinine and (±)-adaline

I. Forbes, A. Holmes, E. Davison, 1995 .

N-alkenyl nitrone dipolar cycloaddition routes to piperidines and indolizidines. Part 7. Hydroxylamine–alkyne cyclisations. Formation of cyclic nitrones and application to the synthesis of the proposed structure for (±)-acacialactam

I. Forbes, A. Holmes, M. Thompson, 1994 .

N‐Alkenyl Nitrone Dipolar Cycloaddition Routes to Piperidines and Indolizidines. Part 7. Hydroxylamine‐Alkyne Cyclizations. Formation of Cyclic Nitrones and Application to the Synthesis of the Proposed Structure for (.+‐.)‐Acacialactam.

I. Forbes, A. Holmes, M. Thompson, 1995 .

Hydroxylamine-alkyne cyclisations. A new method for the synthesis of cyclic nitrones

I. Forbes, A. Holmes, M. Thompson, 1992 .

Hydroxylamine-Alkyne Cyclizations. A New Method for the Synthesis of Cyclic Nitrones.

I. Forbes, A. Holmes, M. Thompson, 1993 .

Targeted replacement of rodent CCR2 with the human orthologue CCR2B: A mouse model for in vivo analysis of human target‐selective small molecule MCP‐1 receptor antagonists

I. Forbes, H. Prosser, P. Groot, 2002 .

Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.

I. Forbes, P. Groot, R. Ife, 2001, Bioorganic & medicinal chemistry letters.

N-Alkenyl Nitrone Dipolar Cycloaddition Routes to Piperidines and Indolizidines. Part 8. The Scope of Tandem Reactions Involving Hydroxylamine-Alkyne Cyclizations.

I. Forbes, A. Holmes, E. Davison, 1996 .

CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.

I. Forbes, F. Blaney, A. Bridges, 2003, Journal of medicinal chemistry.

6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.

F E Blaney, S. Bromidge, I. Forbes, 1997, Journal of medicinal chemistry.

Hydroxylamine-alkyne cyclisations. Synthesis of the seven-membered lactam structure proposed for (±)-acacialactam

J. Ziller, I. Forbes, A. Holmes, 1992 .

An Efficient Synthesis of a-Carboline-3-carboxylic Acid, Ethyl Ester (a-CCE)

I. Forbes, Christopher N. Johnson, M. Thompson, 1993 .

Syntheses of functionalised pyrido[2,3-b]indoles

I. Forbes, Christopher N. Johnson, M. Thompson, 1992 .

Reverse cope elimination of hydroxylamines and alkenes or alkynes: theoretical investigation of tether length and substituent effects.

K N Houk, K. Houk, I. Forbes, 2012, Journal of the American Chemical Society.

Efficient Route for the Preparation of Benzyloxy-Substituted Benzenesulfonyl Chlorides from Mercaptophenols

I. Forbes, Coline Jumeaux, V. Garzya, 2011 .

SYNTHESIS OF THE COUMARINS AVICENNOL, DIPETALINE, AND DIPETALOLACTONE

I. Forbes, R. Murray, 1976 .

Isosteric replacement of the indole nucleus by benzothiophene in a series of pyrido[2,3-b]indoles with potential anxiolytic activity

D. Davies, I. Forbes, T. Blackburn, 1995 .

Regioselective synthesis of an anthraquinone precursor of the anthracyclinones

I. Forbes, R. A. Pratt, R. A. Raphael, 1978 .

A Tandem Synthesis of (.+-.)-Euphococcinine and (.+-.)-Adaline.

I. Forbes, A. Holmes, E. Davison, 1996 .

In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist

I. Forbes, T. Blackburn, G. Kennett, 1994, British journal of pharmacology.

Nitrone dipolar cycloaddition routes to piperidines and indolizidines. Part 9. Formal synthesis of (−)-pinidine and total synthesis of (−)-histrionicotoxin, (+)-histrionicotoxin and (−)-histrionicotoxin 235A

Joseph P. Adams, J. Davies, I. Forbes, 2002 .

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

D. Middlemiss, S. Lightowler, S. Bromidge, 2001, Neuropharmacology.

Synthesis of 8-(3-methylbut-2-enoyl)-7-methoxycoumarin, a novel coumarin from ligusticum hultenii

I. Forbes, R. Murray, 1977 .

Highly stereoselective synthesis of exo and endo indolotropanes

I. Forbes, 1999 .

SB‐656104‐A, a novel selective 5‐HT7 receptor antagonist, modulates REM sleep in rats

J. Hagan, D. Middlemiss, C. Scott, 2003, British journal of pharmacology.

(±)11-Amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, a novel gabaA modulator with potential anxiolytic activity

I. Forbes, T. Blackburn, N. Upton, 1994 .

Studies towards the identification of a new generation of atypical antipsychotic agents.

C. Scorer, J. Hagan, I. Forbes, 2007, Bioorganic & medicinal chemistry letters.

Two novel cassane diterpenoids from Acacia jacquemontii

I. Forbes, K. Joshi, A. Cameron, 1979 .

Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1

M. Whittington, C. Langmead, C. Davies, 2008, British journal of pharmacology.

Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist

C. Langmead, A. Christopoulos, I. Forbes, 2006, Molecular Pharmacology.

N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: a novel, high-affinity 5-HT2B receptor antagonist.

I. Forbes, G. E. Jones, V. Holland, 1995, Journal of medicinal chemistry.

Synthesis and potential anxiolytic activity of 4-amino-pyrido[2,3-b]indoles

I. Forbes, N. Upton, D. Piper, 1993 .

Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.

C. Davies, C. Scott, I. Forbes, 2006, European journal of pharmacology.

Synthesis and evaluation of a series of aryl[e]fused pyrazolo[4,3-c]pyridines with potential anxiolytic activity.

I. Forbes, G. E. Jones, N. Upton, 1990, Journal of medicinal chemistry.

Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.

C. Langmead, I. Forbes, R. Rivero, 2010, ACS medicinal chemistry letters.

A Synthesis of novel IH-Imidazo[1,2-α]Indole-3-Carboxylates

I. Forbes, M. Thompson, H. Morgan, 1996 .

Functional characterisation of the human cloned 5‐HT7 receptor (long form); antagonist profile of SB‐258719

J. Hagan, D. Middlemiss, I. Forbes, 1998, British journal of pharmacology.

In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties

I. Forbes, P. Ham, T. Blackburn, 1996, British Journal of Pharmacology.